introduction: dopamine is one member of catecholamine, which has a crusial role in the regulation of feeding behavior. the peripheral injection of dopamine agonistssuch as bromocriptine causes anorexia. the aim of this study is to show how this drugacts. the reason for this selection is due to its importance in the regulation of food intake. materials & methods: sixty three adult male rats (280...

The therapeutic efficacy of the combination of cyproheptadine and bromocriptine was studied in 15 patients with active acromegaly showing incomplete GH suppression in response to bromocriptine therapy alone. The mean basal plasma GH was 31.3±5.5 µg/L, and it decreased to 19.0±3.9 µg/L during the single bromocriptine therapy (10-20 mg for 2 to 21 months). When cyproheptadine (12 to 16 mg for 8 t...

Thirty-seven patients with Parkinsonism were treated with bromocriptine 2.5-300 mg daily. Bromocriptine, alone or combined with levodopa, caused a 20-30% reduction in disability scores in 11 patients treated for one year. Tolerance did not develop during this period. Bromocriptine treatment was not of value in six patients who had previously not responded or who had lost their response to levod...

Bromocriptine Treatment To the Editor: I read with interest the paper “Centrally Mediated Effects of Bromocriptine on Cardiac Sympathovagal Balance” by Drs Franchi, Lazzeri, Barletta, Ianni, and Mannelli, which was published in July 2001.1 The authors cite a report by Przuntek et al2 published in 1992 that suggested that bromocriptine treatment lessened mortality in patients with Parkinson dise...

Bromocriptine Treatment To the Editor: I read with interest the paper “Centrally Mediated Effects of Bromocriptine on Cardiac Sympathovagal Balance” by Drs Franchi, Lazzeri, Barletta, Ianni, and Mannelli, which was published in July 2001.1 The authors cite a report by Przuntek et al2 published in 1992 that suggested that bromocriptine treatment lessened mortality in patients with Parkinson dise...

Bromocriptine, a dopamine agonist, alleviates symptoms of Parkinson's disease, even when administered alone, and is used for its treatment. Better therapeutic effects are, however, achieved when bromocriptine is used in combination with levodopa. In this study, we examined the biochemical changes caused by bromocriptine administration with and without levodopa, and evaluated the effects of the ...

Treatment with the dopamine receptor D2 (DRD2) agonist bromocriptine improves metabolic features in obese patients with type 2 diabetes by a still unknown mechanism. In the present study, we investigated the acute effect of bromocriptine and its underlying mechanism(s) on insulin secretion both in vivo and in vitro. For this purpose, C57Bl6/J mice were subjected to an intraperitoneal glucose to...

The aim of this study was to investigate the effects of magnesium as a N-Methyl–D-Aspartate (NMDA) receptor Antagnist and bromocriptine as a dopamine receptor agonist on morphine dependence and withdrawal symptoms. In the present study different groups of mice were received morphine (50 mg/kg, i.p.) for four days and on fourth day 1.5 hour after the last morphine administration they received di...

Thirty-one patients with Parkinson's disease were treated with the ergot alkaloid bromocriptine, a drug which stimulates dopamine receptors. Bromocriptine had a slight therapeutic effect in patients on no other treatment and an additional effect in patients on levodopa. The mean optimum dosage of bromocriptine, established over a 12 week period, was 26 mg daily. In 20 patients bromocriptine was...

To ascertain the mechanisms of bromocriptine in lowering serum prolactin (PRL) levels and reducing the cell size of human prolactinomas, stereological analysis at electron microscope level was performed on six adenomas treated with bromocriptine (10 mg/day for 2 weeks) and four untreated adenomas. The bromocriptine treatment significantly decreased all the major organelles involved in PRL synth...